Lindbrook Capital, LLC Mannkind Corp Transaction History

Lindbrook Capital, LLC

$1.18 Billion
Q3 2024

A detailed history of Lindbrook Capital, LLC transactions in Mannkind Corp stock. As of the latest transaction made, Lindbrook Capital, LLC holds 300 shares of MNKD stock, worth $1,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares

300

Previous 98 206.12%

Holding current value

$1,779

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$5.01 - $6.7 $1,012 - $1,353	202 Added 206.12%	300 $1,000
Q2 2024 Jul 31, 2024	BUY	$4.05 - $5.43 $396 - $532	98 New	98 $0
Q4 2022 Jan 24, 2023	BUY	$3.02 - $5.37 $860 - $1,530	285 Added 224.41%	412 $0
Q3 2022 Nov 10, 2022	BUY	$2.99 - $4.35 $379 - $552	127 New	127 $0
Q3 2021 Nov 05, 2021	SELL	$3.89 - $5.48 $389 - $548	-100 Closed	0 $0
Q4 2020 Jan 27, 2021	SELL	$1.79 - $4.04 $8,950 - $20,200	-5,000 Reduced 98.04%	100 $0
Q3 2020 Nov 03, 2020	SELL	$1.56 - $2.08 $15,600 - $20,800	-10,000 Reduced 66.23%	5,100 $10,000
Q2 2020 Jul 27, 2020	BUY	$0.94 - $2.21 $4,700 - $11,050	5,000 Added 49.5%	15,100 $26,000
Q1 2020 Apr 22, 2020	SELL	$0.84 - $1.76 $4,200 - $8,800	-5,000 Reduced 33.11%	10,100 $10,000
Q4 2019 Jan 27, 2020	SELL	$1.14 - $1.49 $615 - $804	-540 Reduced 3.45%	15,100 $19,000
Q3 2019 Oct 31, 2019	BUY	$1.04 - $1.44 $4,160 - $5,760	4,000 Added 34.36%	15,640 $20,000
Q2 2019 Jul 24, 2019	BUY	$1.09 - $1.88 $2,180 - $3,760	2,000 Added 20.75%	11,640 $13,000
Q1 2019 Apr 23, 2019	SELL	$1.14 - $2.25 $2,280 - $4,500	-2,000 Reduced 17.18%	9,640 $18,000
Q4 2018 Feb 07, 2019	BUY	$1.02 - $2.05 $11,872 - $23,861	11,640 New	11,640 $12,000

Others Institutions Holding MNKD

# of Institutions

245

Shares Held

148M

Call Options Held

1.62M

Put Options Held

802K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.53B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account

Lindbrook Capital, LLC Mannkind Corp Transaction History